Retrospective Study of Blood Transfusion Complications in the Capital Region of Denmark from 1999-2017: Characteristics of Potentially “Dangerous” Blood Donors?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Retrospective Study of Blood Transfusion Complications in the Capital Region of Denmark from 1999-2017 : Characteristics of Potentially “Dangerous” Blood Donors? / Have, SB; Egeberg Hother, Christoffer; von Stemann, Jakob Hjorth; Dziegiel, Morten Hanefeld; Hansen, Morten Bagge; Ostrowski, Sisse Rye.

I: Austin Hematology, Bind 6, Nr. 2, 1036, 2021.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Have, SB, Egeberg Hother, C, von Stemann, JH, Dziegiel, MH, Hansen, MB & Ostrowski, SR 2021, 'Retrospective Study of Blood Transfusion Complications in the Capital Region of Denmark from 1999-2017: Characteristics of Potentially “Dangerous” Blood Donors?', Austin Hematology, bind 6, nr. 2, 1036. <https://austinpublishinggroup.com/austin-hematology/fulltext/hematol-v6-id1036.pdf>

APA

Have, SB., Egeberg Hother, C., von Stemann, J. H., Dziegiel, M. H., Hansen, M. B., & Ostrowski, S. R. (2021). Retrospective Study of Blood Transfusion Complications in the Capital Region of Denmark from 1999-2017: Characteristics of Potentially “Dangerous” Blood Donors? Austin Hematology, 6(2), [1036]. https://austinpublishinggroup.com/austin-hematology/fulltext/hematol-v6-id1036.pdf

Vancouver

Have SB, Egeberg Hother C, von Stemann JH, Dziegiel MH, Hansen MB, Ostrowski SR. Retrospective Study of Blood Transfusion Complications in the Capital Region of Denmark from 1999-2017: Characteristics of Potentially “Dangerous” Blood Donors? Austin Hematology. 2021;6(2). 1036.

Author

Have, SB ; Egeberg Hother, Christoffer ; von Stemann, Jakob Hjorth ; Dziegiel, Morten Hanefeld ; Hansen, Morten Bagge ; Ostrowski, Sisse Rye. / Retrospective Study of Blood Transfusion Complications in the Capital Region of Denmark from 1999-2017 : Characteristics of Potentially “Dangerous” Blood Donors?. I: Austin Hematology. 2021 ; Bind 6, Nr. 2.

Bibtex

@article{a3ee17e5a56948439730f524e38ccde3,
title = "Retrospective Study of Blood Transfusion Complications in the Capital Region of Denmark from 1999-2017: Characteristics of Potentially “Dangerous” Blood Donors?",
abstract = "Objectives: We hypothesized that the blood donors most frequently involvedin complications would induce more and severe immunologic transfusioncomplications compared to other donors, i.e. potentially “dangerous”. Secondaryaims were differences in demographic variables.Background: Donor-related mechanisms may contribute to allogeneicblood transfusion complications and may represent a dangerous treatmentadverse event.Materials and Methods: By analyzing transfusion data from the CapitalRegion of Denmark from January 1, 1999 to December 31, 2017; 2,574,646blood transfusions and 9,779 transfusion complications from 194,432 blooddonors were included in our dataset. We divided donors into three groupsbased on the number of complications and complication frequency (potentially“dangerous” vs. two differently defined control groups i.e. control 1 and control2), and compared the nature of transfusion complications and demographicvariables by statistical analysis.Results: There were no differences in the proportion of complicationtypes between the potentially “dangerous” donors and control donors, and nodifference in the proportion of complications from RBCs, plasma or plateletsaccording to ABO and RhD blood types. However, more potentially “dangerous”donors were female and had ABO blood type B compared to control donors(p<0.001 and p<0.01, respectively). The potentially “dangerous” donors wereyounger compared to control donors (40.36 years vs. 45.24 years and 42.84years, p<0.001).Conclusion: The potentially “dangerous” did not display more/severeimmunologic transfusion complications compared to control donors. However,they differed in regards to gender, age and blood type. Further researchregarding the differences in complication frequency per donor and demographicvariety is warranted.",
author = "SB Have and {Egeberg Hother}, Christoffer and {von Stemann}, {Jakob Hjorth} and Dziegiel, {Morten Hanefeld} and Hansen, {Morten Bagge} and Ostrowski, {Sisse Rye}",
year = "2021",
language = "English",
volume = "6",
journal = "Austin Hematology",
number = "2",

}

RIS

TY - JOUR

T1 - Retrospective Study of Blood Transfusion Complications in the Capital Region of Denmark from 1999-2017

T2 - Characteristics of Potentially “Dangerous” Blood Donors?

AU - Have, SB

AU - Egeberg Hother, Christoffer

AU - von Stemann, Jakob Hjorth

AU - Dziegiel, Morten Hanefeld

AU - Hansen, Morten Bagge

AU - Ostrowski, Sisse Rye

PY - 2021

Y1 - 2021

N2 - Objectives: We hypothesized that the blood donors most frequently involvedin complications would induce more and severe immunologic transfusioncomplications compared to other donors, i.e. potentially “dangerous”. Secondaryaims were differences in demographic variables.Background: Donor-related mechanisms may contribute to allogeneicblood transfusion complications and may represent a dangerous treatmentadverse event.Materials and Methods: By analyzing transfusion data from the CapitalRegion of Denmark from January 1, 1999 to December 31, 2017; 2,574,646blood transfusions and 9,779 transfusion complications from 194,432 blooddonors were included in our dataset. We divided donors into three groupsbased on the number of complications and complication frequency (potentially“dangerous” vs. two differently defined control groups i.e. control 1 and control2), and compared the nature of transfusion complications and demographicvariables by statistical analysis.Results: There were no differences in the proportion of complicationtypes between the potentially “dangerous” donors and control donors, and nodifference in the proportion of complications from RBCs, plasma or plateletsaccording to ABO and RhD blood types. However, more potentially “dangerous”donors were female and had ABO blood type B compared to control donors(p<0.001 and p<0.01, respectively). The potentially “dangerous” donors wereyounger compared to control donors (40.36 years vs. 45.24 years and 42.84years, p<0.001).Conclusion: The potentially “dangerous” did not display more/severeimmunologic transfusion complications compared to control donors. However,they differed in regards to gender, age and blood type. Further researchregarding the differences in complication frequency per donor and demographicvariety is warranted.

AB - Objectives: We hypothesized that the blood donors most frequently involvedin complications would induce more and severe immunologic transfusioncomplications compared to other donors, i.e. potentially “dangerous”. Secondaryaims were differences in demographic variables.Background: Donor-related mechanisms may contribute to allogeneicblood transfusion complications and may represent a dangerous treatmentadverse event.Materials and Methods: By analyzing transfusion data from the CapitalRegion of Denmark from January 1, 1999 to December 31, 2017; 2,574,646blood transfusions and 9,779 transfusion complications from 194,432 blooddonors were included in our dataset. We divided donors into three groupsbased on the number of complications and complication frequency (potentially“dangerous” vs. two differently defined control groups i.e. control 1 and control2), and compared the nature of transfusion complications and demographicvariables by statistical analysis.Results: There were no differences in the proportion of complicationtypes between the potentially “dangerous” donors and control donors, and nodifference in the proportion of complications from RBCs, plasma or plateletsaccording to ABO and RhD blood types. However, more potentially “dangerous”donors were female and had ABO blood type B compared to control donors(p<0.001 and p<0.01, respectively). The potentially “dangerous” donors wereyounger compared to control donors (40.36 years vs. 45.24 years and 42.84years, p<0.001).Conclusion: The potentially “dangerous” did not display more/severeimmunologic transfusion complications compared to control donors. However,they differed in regards to gender, age and blood type. Further researchregarding the differences in complication frequency per donor and demographicvariety is warranted.

M3 - Journal article

VL - 6

JO - Austin Hematology

JF - Austin Hematology

IS - 2

M1 - 1036

ER -

ID: 302575898